Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


France and Australia double Global Fund contributions:

This article was originally published in Clinica

Executive Summary

France and Australia are among the latest countries to answer calls from the Global Fund to Fight AIDS, Malaria and Tuberculosis for the world's wealthier countries to increase their contributions. France has pledged to "significantly increase" its contributions in 2006 rising to Euro300m (US$376m) by 2007 - thereby doubling the amount it contributed in each of 2004 and 2005. Australia too has pledged to double its commitment, allocating a further Aus$50m (US$39m) over three years. The pledges come ahead of last week's so-called replenishment conference in Rome. The event will seek to drum up international support for the organisation in the run-up to a final conference in London in September 2005, as it faces challenging funding targets. Current commitments stand at US$2.3bn in 2005, US$3.5bn in 2006 and US$3.6bn in 2007.

You may also be interested in...

FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time

In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts